Depletion of the receptor for advanced glycation end products (RAGE) sensitizes towards apoptosis via p53 and p73 posttranslational regulation

Oncogene

Volumn 32, Issue 11, 2013, Pages 1460-1468

  Brune, M ^a   Muller M ^a,b   Melino, G ^c,d   Bierhaus, A ^a   Schilling, T ^a   Nawroth, P P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c MRC TOXICOLOGY UNIT   (United Kingdom)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

apoptosis; CD95; p53; p73; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CASPASE; FAS ANTIGEN; PROTEIN BCL 2; PROTEIN P53; PROTEIN P73; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; ENZYME ACTIVATION; GENE SILENCING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN PROCESSING; PROTEIN TRANSPORT; TRANSACTIVATION; UBIQUITINATION;

ANIMALS; APOPTOSIS; CELLS, CULTURED; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE DELETION; MICE; MICE, KNOCKOUT; NUCLEAR PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; RECEPTORS, IMMUNOLOGIC; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

MURINAE;

EID: 84875221298     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.150     Document Type: Article

References (44)

1. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YCE et al. Cloning and expression of a cell-surface receptor for advanced glycosylation end-products of proteins. J Biol Chem 1992; 267: 14998-15004.
2. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J et al. Isolation and characterization of 2 binding-proteins for advanced glycosylation end-products from bovine lung which are present on the endothelial-cell surface. J Biol Chem 1992; 267: 14987-14997.
3. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005; 83: 876-886. (Pubitemid 41598688)
4. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113: 1641-1650. (Pubitemid 39071688)
5. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009; 52: 2251-2263.
6. Ding KH, Wang ZZ, Hamrick MW, Deng ZB, Zhou L, Kang BL et al. Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun 2006; 340: 1091-1097. (Pubitemid 43083390)
7. Eggers K, Sikora K, Lorenz M, Taubert T, Moobed M, Baumann G et al. RAGEdependent regulation of calcium-binding proteins S100A8 and S100A9 in human THP-1. Exp Clin Endocrinol Diabetes 2011; 119: 353-357.
8. Schmidt AM, Du Yan S, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-955. (Pubitemid 32946067)
9. Soro-Paavonen A, Watson AMD, Li J, Paavonen K, Koitka A, Calkin AC et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008; 57: 2461-2469.
10. Sparvero LJ, Asafu-Adjei D, Kang R, Tang DL, Amin N, Im J et al. RAGE (receptor for advanced glycation endproducts), RAGE Ligands, and their role in Cancer and Inflammation. J Transl Med 2009; 7: 17.
11. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000; 275: 40096-40105. (Pubitemid 32064635)
12. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W et al. Blockade of RAGEamphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-360. (Pubitemid 30337069)
13. Kang R, Tang D, Lotze MT, Zeh III HJ. RAGE regulates autophagy and apoptosis following oxidative injury. Autophagy 2011; 7: 442-444.
14. Kang R, Tang D, Loze MT, Zeh HJ. Apoptosis to autophagy switch triggered by the MHC class III-encoded receptor for advanced glycation endproducts (RAGE). Autophagy 2011; 7: 91-93.
15. Alikhani M, Alikhani Z, Boyd C, MacLellan CM, Raptis M, Liu R et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 2007; 40: 345-353. (Pubitemid 46054556)
16. Barnes PJ, Larin M. Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases. N Eng J Med 1997; 336: 1066-1071. (Pubitemid 27163860)
17. Cheng B, Pan S, Liu X, Zhang S, Sun X. Cell apoptosis of taste buds in circumvallate papillae in diabetic rats. Exp Clin Endocrinol Diabetes 2011; 119: 480-483.
18. Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett 2003; 550: 107-113. (Pubitemid 37281366)
19. Karin M. Nuclear factor-kappa B in cancer development and progression. Nature 2006; 441: 431-436. (Pubitemid 44050137)
20. Zhou Z, Immel D, Xi CX, Bierhaus A, Feng X, Mei L et al. Regulation of osteoclast function and bone mass by RAGE. J Exp Med 2006; 203: 1067-1080.
21. Paul RG, Bailey AJ. Glycation of collagen: The basis of its central role in the late complications of ageing and diabetes. Int J Biochem Cell Biol 1996; 28: 1297-1310. (Pubitemid 27037919)
22. Gulcelik NE, Bayraktar M, Caglar O, Alpaslan M, Karakaya J. Mortality after hip fracture in diabetic patients. Exp Clin Endocrinol Diabetes 2011; 119: 414-418.
23. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 2007; 22: 1317-1328. (Pubitemid 351339677)
24. Stolzing A, Sellers D, Llewelyn O, Scutt A. Diabetes induced changes in rat mesenchymal stem cells. Cells Tissues Organs 2010; 191: 453-465.
25. Bentires-Alj M, Dejardin E, Viatour P, Van Lint C, Froesch B, Reed JC et al. Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. Oncogene 2001; 20: 2805-2813. (Pubitemid 32549837)
26. Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2010; 17: 666-676.
27. Hiwatashi K, Ueno S, Kubo F, Sakoda M, Tateno T, Hayashi T et al. Relevance of apoptosis and tolerance to hypoxic stress in cells transfected with Receptor for Advanced Glycation End Products (RAGE). Anticancer Res 2009; 29: 1287-1294.
28. Chan H, Bartos DP, Owen-Schaub LB. Activation-dependent transcriptional regulation of the human fas promoter requires NF-kappa B p50-p65 recruitment. Mol Cell Biol 1999; 19: 2098-2108. (Pubitemid 29098268)
29. Lavrik IN, Golks A, Baumann S, Krammer PH. Caspase-2 is activated at the CD95 death-inducing signaling complex in the course of CD95-induced apoptosis. Blood 2006; 108: 559-565. (Pubitemid 44061356)
30. Seitz SJ, Schleithoff ES, Koch A, Schuster A, Teufel A, Staib F et al. Chemotherapyinduced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int J Cancer 2010; 126: 2049-2066.
31. Lavrik IN, Golks A, Riess D, Bentele M, Eils R, Krammer PH. Analysis of CD95 threshold signaling - Triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling. J Biol Chem 2007; 282: 13664-13671. (Pubitemid 47100557)
32. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K et al. RAGE signaling sustains inflammation and promotes tumor development. J Exper Med 2008; 205: 275-285. (Pubitemid 351281593)
33. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-1805. (Pubitemid 24163411)
34. Kikuchi H, Ozaki T, Furuya K, Hanamoto T, Nakanishi M, Yamamoto H et al. NFkappa B regulates the stability and activity of p73 by inducing its proteolytic degradation through a ubiquitin-dependent proteasome pathway. Oncogene 2006; 25: 7608-7617. (Pubitemid 44924474)
35. Dudley E, Hornung F, Zheng L, Scherer D, Ballard D, Lenardo M. NF-kappaB regulates Fas/APO-1/CD95- and TCR- mediated apoptosis of T lymphocytes. Eur J Immunol 1999; 29: 878-886. (Pubitemid 29119067)
36. Rensing-Ehl A, Hess S, Ziegler-Heitbrock HW, Riethmuller G, Engelmann H. Fas/Apo-1 activates nuclear factor kappa B and induces interleukin-6 production. J Inflamm 1995; 45: 161-174.
37. Tsoporis JN, Izhar S, Leong-Poi H, Desjardins JF, Huttunen HJ, Parker TG. S100B interaction with the receptor for advanced glycation end products (RAGE): A novel receptor-mediated mechanism for myocyte apoptosis postinfarction. Circ Res 2010; 106: 93-101.
38. Constien R, Forde A, Liliensiek B, Grone HJ, Nawroth P, Hammerling G et al. Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 2001; 30: 36-44.
39. Borcsok I, Schairer HU, Sommer U, Wakley GK, Schneider U, Geiger F et al. Glucocorticoids regulate the expression of the human osteoblastic endothelin A receptor gene. J Exper Med 1998; 188: 1563-1573. (Pubitemid 28516101)
40. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 2009; 16: 1093-1107.
41. Muller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H et al. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 2005; 12: 1564-1577. (Pubitemid 41679162)
42. Mundt HM, Stremmel W, Melino G, Krammer PH, Schilling T, Muller M. Dominant negative (DeltaN) p63alpha induces drug resistance in hepatocellular carcinoma by interference with apoptosis signaling pathways. Biochem Biophys Res Commun 2010; 396: 335-341.
43. Munsch D, Watanabe-Fukunaga R, Bourdon JC, Nagata S, May E, Yonish-Rouach E et al. Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis. J Biol Chem 2000; 275: 3867-3872. (Pubitemid 30094610)
44. Villa-Morales M, Santos J, Fernandez-Piqueras J. Functional Fas (Cd95/Apo-1) promoter polymorphisms in inbred mouse strains exhibiting different susceptibility to gamma-radiation-induced thymic lymphoma. Oncogene 2006; 25: 2022-2029.